Tissue engineering to replace cells lost in cancer therapy is important because surgery and radiation usually cause tissue loss and damage. Tissue from donors can cause immune repulsion.  Converting somatic cells, such as skin fibroblast from cancer patient to induced pluripotent stem (iPS) cells, makes it possible to generate tissues for autologous transplantation without causing immune response.  We introduced Oct4, Sox2, and Klf4 genes, whose expression is under doxycycline-inducible promoters, into skin fibroblast using lentivirus to generate human iPS cells.   These iPS cells have similar characteristics with human ES cells.  We also differentiated these human iPS cells into fibroblast cells which can be induced to iPS cells upon doxycycline treatment.  The inducible iPS cell system not only allow us to use these cells for replacement therapy, but also provide an inducible system to investigate the molecular mechanisms of iPS cell induction.

Establishment of inducible iPS cells for tissue engineering for cancer therapy

243rd National Meeting (2012)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.